key: cord-1050535-j7scy52i authors: Montoya, José G.; Adams, Amy E.; Bonetti, Valérie; Deng, Sien; Link, Nan A.; Pertsch, Suzanne; Olson, Kjerstie; Li, Martina; Dillon, Ellis C.; Frosch, Dominick L. title: Differences in IgG antibody responses following BNT162b2 and mRNA-1273 Vaccines date: 2021-06-19 journal: bioRxiv DOI: 10.1101/2021.06.18.449086 sha: 9ad9e4afc233595516846fc6909cb0c166495856 doc_id: 1050535 cord_uid: j7scy52i Studies examining antibody responses by vaccine brand are lacking and may be informative for optimizing vaccine selection, dosage, and regimens. The purpose of this study is to assess IgG antibody responses following immunization with BNT162b2 (30 μg S protein) and mRNA-1273 (100 μg S protein) vaccines. A cohort of clinicians at a non-for-profit organization is being assessed clinically and serologically following immunization with BNT162b2 or mRNA-1273. IgG responses were measured at the Remington Laboratory by an IgG against the SARS-CoV-2 spike protein-receptor binding domain. Mixed-effect linear (MEL) regression modeling was used to examine whether the SARS-CoV-2 IgG level differed by vaccine brand, dosage, or days since vaccination. Among 532 SARS-CoV-2 seronegative participants, 530 (99.6%) seroconverted with either vaccine. After adjustments for age and gender MEL regression modeling revealed that the average IgG increased after the second dose compared to the first dose (p<0.001). Overall, titers peaked at week six for both vaccines. Titers were significantly higher for mRNA-1273 vaccine on days 14-20 (p < 0.05), 42-48 (p < 0.01), 70-76 (p < 0.05), 77-83 (p < 0.05), and higher for BNT162b2 vaccine on days 28-34 (p < 0.001). In two participants taking immunosuppressive drugs SARS-CoV-2 IgG remained negative. mRNA-1273 elicited both earlier and higher IgG antibody responses than BNT162b2, possibly due to the higher S-protein delivery. Prospective clinical and serological follow-up of defined cohorts such as this may prove useful in determining antibody protection and whether differences in antibody kinetics between the vaccines have manufacturing relevance and clinical significance. SARS-CoV-2 IgG remained negative. mRNA-1273 elicited both earlier and higher IgG 48 antibody responses than BNT162b2, possibly due to the higher S-protein delivery. 49 Prospective clinical and serological follow-up of defined cohorts such as this may prove 50 useful in determining antibody protection and whether differences in antibody kinetics 51 between the vaccines have manufacturing relevance and clinical significance. Within one year of the emergence of SARS-CoV-2 two novel and effective mRNA 60 vaccines became available, BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna) 61 (1, 2). BNT162b2 is translated into 30 μg of SARS-CoV-2 full-length spike (pre-fusion 62 conformation) and boosted three weeks after (3). mRNA-1273 is translated into 100 μg 63 of pre-fusion-stabilized spike glycoprotein and boosted four weeks later (4). Healthcare workers were the first group to receive BNT162b2 and mRNA-1273 (1). The present study was launched on 12/10/20, the week that SARS-CoV-2 vaccines 66 became available, providing the opportunity to assess antibody responses in 67 participants receiving two different vaccine brands, before and after immunization. Most 68 studies so far have focused on following IgG antibody responses to single vaccine 69 brands (5-8). This study examines how antibody responses vary by vaccine brand, 70 dosage, and days since vaccination. A longitudinal study was initiated to estimate the incidence of SARS-CoV-2 73 infection and COVID-19 by serological testing. Additionally, it aims to assess SARS- CoV-2 antibody responses and sustainability following infection or immunization. Here we report IgG responses following immunization within the first three months of the 76 study. The study protocol was approved by the Sutter Health IRB. were excluded from the model for this report. Among 656 clinicians who consented to participate, 611 (93.1%) completed their 108 baseline survey and serum collection. Mean age of participants was 47.4 years. Approximately two-thirds were female (Table 1) . Participants self-identified as primarily Considering that BNT162b2 is boosted one week earlier than mRNA-1273 may 148 explain why the differences in responses were not even wider in favor of mRNA-1273. If 149 protection requires maintaining antibody levels above a certain threshold, higher initial 150 levels of response following vaccination or frequent boosting may succeed in keeping 151 antibody levels above this threshold for longer than after natural infection (12) despite 152 similar rates of antibody decay. Moreover, even small differences in antibody titers may 153 translate into wider divergence of protection due to amplifiable immune cascades. Limitations of our paper include that we do not yet have the clinical correlates of 155 immunity that we expect to accrue longitudinally over a minimum of one-year follow-up. Additionally, the clinicians who did not seroconvert due to immunosuppression, did not following immunization in specific cohorts, while tracking clinical correlates, may help to 164 identify individuals who have titer levels that become non-protective. This strategy may 165 serve as the basis to have them studied with other correlates of immune protection (e.g. 166 T-cells) (13) or be candidates for additional doses. To achieve these goals (12, 13), only 167 serological assays targeting the spike protein and with demonstrated sensitivity and 168 specificity, such as the one used for our study, ought to be utilized. Ongoing studies 169 such as ours, can potentially unveil differences in IgG responses between vaccine 170 brands (as observed in this interim report) that may be relevant clinically or for 171 manufacturing purposes (e.g., choice of antigen amount). The Advisory Committee on Immunization Practices' 190 Updated Interim Recommendation for Allocation of COVID-19 Vaccine -United States Audio Interview: Advice for Clinicians on Covid-19 Vaccines and Social Restrictions Safety 198 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Efficacy and Safety of the 204 mRNA-1273 SARS-CoV-2 Vaccine Safety and immunogenicity of the ChAdOx1 nCoV-19 210 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, 211 randomised controlled trial Poor antigen-214 specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-215 experienced individuals Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19 A 224 preliminary report of a randomized controlled phase 2 trial of the safety and 225 immunogenicity of mRNA-1273 SARS-CoV-2 vaccine Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-234 2 Clinical immunology of the 236 sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection Adaptive immunity to SARS-CoV-2 and COVID-19 174 We thank the clinicians who have volunteered and are participating in our study, Palo